Chinese Journal of Cancer Research

, Volume 12, Issue 3, pp 183–187 | Cite as

Effects of IFN-α combined with il-6 on growth and expression of the genes related to cell-growth and apoptosis of bone marrow cells from patients with CML

  • Chen Han-chun 
  • Tang Li-jun 
  • Peng Xing-hua 
  • Luo Zhi-yong 
  • Luo Sai-qun 
  • Tan Wen-bin 
Advances in Brief


Objective: To investigate the effects of interferon-α (IFN-α) and IFN-α combined with interleukin-6 (IL-6) on growth and expression of bcr-abl, bcl-2 and c-myc genes in the mononuclear cells (MNCs) from bone marrow (BM) of patients with chronic myelogenous leukemia (CML). Methods: MNCs were collected from BM of the patients with CML in chronic phase by centrifugation in lymphocyte separation medium and cultured in liquid with IFN-α (200U/ml) or IFN-α (200U/ml) plus IL-6 (100 ng/ml). The growing cells were counted every day. The expression levels of β-actin, bcr-abl, bcl-2 and c-myc genes in the MNCs incubated for 24 h were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and relatively quantitative analysis of the amplified fragments by optical density scanning for the bands on gel. Results: The cell growth was markedly suppressed by IFN-α but the degree of cell-growth inhibition was slightly decreased by IL-6 on the basis of IFN-α effect The expression of bcr-abl chimeric gene was intensely inhibited by IFN-α or IFN-α plus IL-6. The expression of bcl-2 gene was suppressed by either IFN-α or IFN-α plus IL-6, whereas that of c-myc gene was also inhibited by IFN-α but strongly elevated by IL-6 on the basis of IFN-α action. Conclusions: Both IFN-α and IFN-α plus IL-6 can inhibit the expression of anti-apoptosis gene such as bcr-abl and bcl-2 and regulate the expression of the gene related to cell proliferation and differentiation such as c-myc. Either IFN-α or IFN-α combined with IL-6 will serve as a trustful strategy of clinical treatment for CML.

Key words

Chronic myelogenous leukemia Combination therapy Interferon-a Interleukin-6 Gene expression Apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Rowley ID. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 1973; 243:290.PubMedCrossRefGoogle Scholar
  2. [2]
    Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 1986; 233:212.PubMedCrossRefGoogle Scholar
  3. [3]
    McWhirter JR, Wang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion protein. Mol Cell Biol 1991; 11:1553.PubMedGoogle Scholar
  4. [4]
    McGahon A, Bissonette R, Schmitt M, et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179.PubMedGoogle Scholar
  5. [5]
    Tura S, Baccarani M, Zutfa E, et al. Interferon alfa-2a as compared with conventional chemotherapy for treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820.CrossRefGoogle Scholar
  6. [6]
    Yanagisawa K, Yamauchi H, Kaneko M, et al. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-a. Blood 1998; 91:641.PubMedGoogle Scholar
  7. [7]
    Anand M, Chodda SK, Parikh PM, et al. Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myelogenous leukemia in different stages, and their role in prognosis. Hematol Oncol 1998; 16:143.PubMedCrossRefGoogle Scholar
  8. [8]
    Tsuberi B, Naparstek E. Modification of Ml cells by exogenous introduction of IL-6 gene: a model for gene therapy of acute and chronic myeloid leukemia in mice. Leukemia 1995; Suppl 1:s93.Google Scholar
  9. [9]
    Cambier N, Zhang Y, Vairo G, et al. Expression of BCR-ABL in Ml myeloid leukemia cells induces differentiation without arresting proliferation. Oncogene 1999; 18:343.PubMedCrossRefGoogle Scholar
  10. [10]
    Selleri C, Sato T, Vecchi LD, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-a in chronic myelogenous leukemia. Blood 1997; 89:957.PubMedGoogle Scholar
  11. [11]
    Enright H, McGlave PB. Biology and treatment of chronic myelogenous leukemia. Oncology 1997; 11:1295.PubMedGoogle Scholar
  12. [12]
    Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 1996; 93:2239.PubMedCrossRefGoogle Scholar
  13. [13]
    Kantarjian HM, Smith TL, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. Ann Intern Med 1995; 122:254.PubMedGoogle Scholar
  14. [14]
    Talpaz M, McCredie K, Kantarjian H, et al. Chronic myelogenous leukemia: hematological remissions with alpha interferon. Br J Hematol 1986; 64:87.CrossRefGoogle Scholar
  15. [15]
    Selleri C, Jaroslow P, Maciejewski, et al. Fas-mediated modulation of bcr/abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood 1998; 92:981.PubMedGoogle Scholar
  16. [16]
    Hanchun Chen, Andrew Pierce, Tony Whetton. Study on the treatment of MT/p210bcr-abl transgenic micein vivo by 5-fluorouracil. Life Science Res 1999; 3:36.Google Scholar

Copyright information

© Chinese Journal of Cancer Research 2000

Authors and Affiliations

  • Chen Han-chun 
    • 1
  • Tang Li-jun 
    • 1
  • Peng Xing-hua 
    • 1
  • Luo Zhi-yong 
    • 1
  • Luo Sai-qun 
    • 1
  • Tan Wen-bin 
    • 1
  1. 1.Research Center for Molecular BiologyHunan Medical UniversityChangshaChina

Personalised recommendations